{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:29:48Z","timestamp":1789694988176,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minufiya University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a spectrum of hepatic disorders that are closely linked to metabolic risk factors. This study aimed to investigate the stratified cardiovascular risk in patients with MASLD based on varying metabolic risk burdens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a cross-sectional analysis, 357 patients with MASLD were classified into three subtypes based on the number of metabolic conditions used for diagnosis: subtype 1 with one metabolic risk factor (n\u2009=\u2009110), subtype 2 with two (n\u2009=\u2009161), and subtype 3 with three risk factors (n\u2009=\u200986). Clinical parameters, liver enzymes, lipid profiles, and 10-year risk of Atherosclerotic Cardiovascular Disease (ASCVD) were compared among subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of diabetes and hypertension increased significantly across subtypes, with subtype 3 showing the highest burden of cardiovascular risk factors (100% diabetes, 43% hypertension). Cardiovascular risk was elevated in subtype 3 (mean ASCVD 0.112\u2009\u00b1\u20090.108, p\u2009&lt;\u20090.001). Multivariate analysis identified subtype 3 (OR\u2009=\u20097.812, 95% CI 1.980\u201330.819, p\u2009=\u20090.003), men sex (OR\u2009=\u200933.549, 95% CI 11.814\u201395.269, p\u2009&lt;\u20090.001), and age (OR\u2009=\u20091.171, 95% CI 1.116\u20131.229, p\u2009&lt;\u20090.001) as independent predictors of intermediate to high cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The metabolic burden in patients with MASLD significantly stratified cardiovascular risk. Patients with the highest metabolic dysfunction are at increased risk of cardiovascular events, underscoring the need for targeted cardiovascular prevention strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-025-03151-9","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T03:23:19Z","timestamp":1758597799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Stratified cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): impact of varying metabolic risk factor burden"],"prefix":"10.1186","volume":"30","author":[{"given":"Maha","family":"Elsabaawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Torkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Magdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Naguib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"6","key":"3151_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"issue":"4","key":"3151_CR2","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1097\/HEP.0000000000000234","volume":"78","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of MASLD: a systematic review and meta-analysis. Hepatology. 2023;78(4):1510\u201325. https:\/\/doi.org\/10.1097\/HEP.0000000000000234.","journal-title":"Hepatology"},{"issue":"8","key":"3151_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41569-023-00874-2","volume":"20","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Byrne CD, Targher G. MASLD and risk of cardiovascular disease: mechanisms and implications. Nat Rev Cardiol. 2023;20(8):487\u2013509. https:\/\/doi.org\/10.1038\/s41569-023-00874-2.","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"3151_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S2468-1253(23)00183-2","volume":"8","author":"M Eslam","year":"2023","unstructured":"Eslam M, El-Serag HB, Francque S, et al. Metabolic dysfunction-associated steatotic liver disease: mechanisms and heterogeneity. Lancet Gastroenterol Hepatol. 2023;8(11):927\u201343. https:\/\/doi.org\/10.1016\/S2468-1253(23)00183-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"3151_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.eprac.2023.08.003","volume":"29","author":"K Cusi","year":"2023","unstructured":"Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of MASLD. Endocr Pract. 2023;29(12):1016\u201332. https:\/\/doi.org\/10.1016\/j.eprac.2023.08.003.","journal-title":"Endocr Pract"},{"key":"3151_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000234","author":"MS Siddiqui","year":"2023","unstructured":"Siddiqui MS, Harrison SA, Abdelmalek MF, et al. Ultrasound vs MRI-PDFF for steatosis detection in MASLD. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000234.","journal-title":"Hepatology"},{"issue":"1","key":"3151_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jhep.2022.08.030","volume":"78","author":"L Castera","year":"2023","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Non-invasive assessment of liver disease in MASLD. J Hepatol. 2023;78(1):196\u2013214. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.030.","journal-title":"J Hepatol"},{"issue":"9","key":"3151_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S2468-1253(21)00130-2","volume":"6","author":"S Lim","year":"2021","unstructured":"Lim S, Lee YH, Kim YJ, et al. Metabolic dysfunction\u2013associated steatotic liver disease predicts long-term mortality and cardiovascular disease. Lancet Gastroenterol Hepatol. 2021;6(9):735\u201345. https:\/\/doi.org\/10.1016\/S2468-1253(21)00130-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"3151_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412\u20139. https:\/\/doi.org\/10.1007\/BF00280883.","journal-title":"Diabetologia"},{"issue":"6","key":"3151_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325. https:\/\/doi.org\/10.1002\/hep.21178.","journal-title":"Hepatology"},{"issue":"4","key":"3151_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u201354. https:\/\/doi.org\/10.1002\/hep.21496.","journal-title":"Hepatology"},{"key":"3151_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. https:\/\/doi.org\/10.1186\/1471-230X-6-33.","journal-title":"BMC Gastroenterol"},{"key":"3151_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437741.48606.98","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology\/American heart association task force on practice guidelines. Circulation. 2014. https:\/\/doi.org\/10.1161\/01.cir.0000437741.48606.98.","journal-title":"Circulation"},{"issue":"3","key":"3151_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589\u2013600. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.013.","journal-title":"J Hepatol"},{"issue":"2","key":"3151_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4093\/dmj.2021.0327","volume":"47","author":"KS Kim","year":"2023","unstructured":"Kim KS, Hong S, Ahn HY, et al. Metabolic dysfunction-associated steatotic liver disease and mortality: a population-based cohort study. Diabetes Metab J. 2023;47(2):220\u201331. https:\/\/doi.org\/10.4093\/dmj.2021.0327.","journal-title":"Diabetes Metab J"},{"issue":"11","key":"3151_CR16","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.14309\/ajg.0000000000000401","volume":"114","author":"AM Allen","year":"2019","unstructured":"Allen AM, Therneau TM, Mara KC, et al. Women with nonalcoholic fatty liver disease lose protection against cardiovascular disease: a longitudinal cohort study. Am J Gastroenterol. 2019;114(11):1764\u201371. https:\/\/doi.org\/10.14309\/ajg.0000000000000401.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3151_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MASLD and the risk of CVD. Hepatol Int. 2023;17(4):773\u201391. https:\/\/doi.org\/10.1007\/s12072-023-10543-8.","journal-title":"Hepatol Int"},{"issue":"10","key":"3151_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","volume":"19","author":"M Eslam","year":"2022","unstructured":"Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638\u201351. https:\/\/doi.org\/10.1038\/s41575-022-00635-5.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"3151_CR19","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa004","volume":"41","author":"M Bl\u00fcher","year":"2020","unstructured":"Bl\u00fcher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3):bnaa004. https:\/\/doi.org\/10.1210\/endrev\/bnaa004.","journal-title":"Endocr Rev"},{"issue":"3","key":"3151_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S2213-8587(17)30292-9","volume":"6","author":"N Stefan","year":"2018","unstructured":"Stefan N, H\u00e4ring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018;6(3):249\u201358. https:\/\/doi.org\/10.1016\/S2213-8587(17)30292-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"3151_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","volume":"126","author":"JP Despr\u00e9s","year":"2012","unstructured":"Despr\u00e9s JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.067264.","journal-title":"Circulation"},{"issue":"9","key":"3151_CR22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","volume":"7","author":"IJ Neeland","year":"2019","unstructured":"Neeland IJ, Ross R, Despr\u00e9s JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715\u201325. https:\/\/doi.org\/10.1016\/S2213-8587(19)30084-1.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"3151_CR23","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/liv.15862","volume":"44","author":"Z Pan","year":"2024","unstructured":"Pan Z, Liu Y, Zhang Q, et al. MASLD predicts cardiovascular disease risk better than NAFLD. Liver Int. 2024;44(7):1567\u201374. https:\/\/doi.org\/10.1111\/liv.15862.","journal-title":"Liver Int"},{"issue":"15","key":"3151_CR24","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.jacc.2023.07.018","volume":"82","author":"JR Medina-Inojosa","year":"2023","unstructured":"Medina-Inojosa JR, Somers VK, Garcia M, et al. Performance of the ACC\/AHA pooled cohort cardiovascular risk equations in clinical practice. J Am Coll Cardiol. 2023;82(15):1499\u2013508. https:\/\/doi.org\/10.1016\/j.jacc.2023.07.018.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"3151_CR25","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.3390\/nu16142220","volume":"16","author":"M Beygi","year":"2024","unstructured":"Beygi M, Ahi S, Zolghadri S, Stanek A. Management of metabolic-associated fatty liver disease\/metabolic dysfunction-associated steatotic liver disease: from medication therapy to nutritional interventions. Nutrients. 2024;16(14):2220. https:\/\/doi.org\/10.3390\/nu16142220.","journal-title":"Nutrients"},{"issue":"1","key":"3151_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","volume":"140","author":"CD Williams","year":"2011","unstructured":"Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124\u201331. https:\/\/doi.org\/10.1053\/j.gastro.2010.09.038.","journal-title":"Gastroenterology"},{"issue":"1","key":"3151_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/hep.31746","volume":"74","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Stepanova M, Lam B, et al. Nonalcoholic fatty liver disease is the fastest growing cause of hepatocellular carcinoma and liver transplantation in the USA. Hepatology. 2021;74(1):129\u201338. https:\/\/doi.org\/10.1002\/hep.31746.","journal-title":"Hepatology"},{"issue":"2","key":"3151_CR28","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhep.2023.10.012","volume":"80","author":"RJ Wong","year":"2023","unstructured":"Wong RJ, Singal AK, Ahmed A. Trends in liver transplantation for MASLD in the U.S.,2010\u20132022. J Hepatol. 2023;80(2):456\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2023.10.012.","journal-title":"J Hepatol"},{"issue":"3","key":"3151_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5114\/ceh.2023.130744","volume":"9","author":"A P\u0142atek","year":"2023","unstructured":"P\u0142atek A, Szyma\u0144ska A. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor. Clin Exp Hepatol. 2023;9(3):187\u201392. https:\/\/doi.org\/10.5114\/ceh.2023.130744.","journal-title":"Clin Exp Hepatol"},{"issue":"17","key":"3151_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16173104","volume":"16","author":"C Tana","year":"2019","unstructured":"Tana C, Ballestri S, Ricci F, et al. Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health. 2019;16(17):3104. https:\/\/doi.org\/10.3390\/ijerph16173104.","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"3151_CR31","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1111\/dom.14830","volume":"24","author":"VR Aroda","year":"2022","unstructured":"Aroda VR, Eckel RH. Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: a 21st century assessment. Diabetes Obes Metab. 2022;24(12):2297\u2013308. https:\/\/doi.org\/10.1111\/dom.14830.","journal-title":"Diabetes Obes Metab"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03151-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T12:11:19Z","timestamp":1758715879000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03151-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3151"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03151-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cThis study was conducted per the principles of the Declaration of Helsinki. This study was approved by the Ethics Committee of the National Liver Institute, Menoufia University as unique research and not a part of an approved student thesis. Informed consent was obtained from all patients or their legal representatives before enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"847"}}